

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 74726

Title: Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 00077376

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Professor

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2022-01-07

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-01-14 02:03

Reviewer performed review: 2022-01-20 05:46

Review time: 6 Days and 3 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Immunotherapy has been raised as a breakthrough of cancer therapy, which warrants further exploration for PDAC treatment. However, immunotherapy for PDAC is largely limited by its immune evasion barrier. This review is well written for helping us to understand the diverse mechanisms underlying the immune evasion in PDAC, focusing on targeting histone deacetylase (HDAC) as a strategy to reverse immune evasion in PDAC. The following is the minor comment to this review. # Figures 1, 2 and 3 seem to be originally drawn by the authors; however, the concept is based on the results of previous studies. Therefore, it is recommended that several references should be cited like “This figure is an original creation based on these references”.

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 74726

Title: Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04876783

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Poland

Author's Country/Territory: China

Manuscript submission date: 2022-01-07

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-01-14 09:30

Reviewer performed review: 2022-01-23 19:47

Review time: 9 Days and 10 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The review of Sim W and co-workers, discusses current state of the art in pancreatic cancer treatment progress from the level of immune response and histone deacetylase inhibitors (HDACi) potential. The paper is very interesting and contains a number of valuable information briefly summarizing achievements and failures of the ongoing anticancer treatment in pancreatic cancer that take advantage of the HDACi. - The content of the article well matches to the profile of the journal, and quite well meets the formula of the review paper. - The introduction is coherent and very well bring s to the topic of the paper. - Included table and figures well illustrate ethos of the review, summarize the data and increase the quality and clarity of the paper. - The references are properly chosen. Comments: - The effect of HDACi on angiogenesis is minimally mentioned and despite of the non-specific effect should be developed. - Also the mRNA vaccines for pancreatic cancer are not indicated at least against KRAS mutations, as the authors describe the gentic background of the disease. - Some typing errors should be removed before publication, e.g. in abstract "We review the evidence on HDAC inhibitors in tumor eradication "tumor"?..... Sometimes histone deacetylase is in singular and should be in plural, please put an attention and check, also regarding abbreviation. I do recommend the publication of the paper in the World Journal of Gastroenterology after minor revision.